Generalized Anxiety Disorder Severity Scale (GADSS): A preliminary validation study

Depression and Anxiety

Volumn 23, Issue 2, 2006, Pages 77-82

  Shear, Katherine ^a   Belnap, Bea Herbeck ^b   Mazumdar, Sati ^c   Houck, Patricia ^b   Rollman, Bruce L ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Generalized anxiety disorder; Outcome measures; Rating scale

Indexed keywords

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; GENERALIZED ANXIETY DISORDER SEVERITY SCALE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANIC DISORDER SEVERITY SCALE; PRIORITY JOURNAL; RATING SCALE; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TELEPHONE; VALIDATION PROCESS;

ANXIETY DISORDERS; FOLLOW-UP STUDIES; HUMANS; INTERVIEW, PSYCHOLOGICAL; INTERVIEWS; PANIC DISORDER; SEVERITY OF ILLNESS INDEX;

EID: 33645097561     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20149     Document Type: Article

References (26)

1. American Psychiatric Association. 1980. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: Author.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Author.
3. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th text rev. ed. Washington, DC: Author.
4. Brown TA, Antony MM, Barlow DH. 1992. Psychometric properties of the Penn State Worry Questionnaire in a clinical anxiety disorders sample. Behav Res Ther 30:33-37.
5. Davidson JR. 2004. Generalized anxiety and panic: Common, costly, and challenging disorders and their pharmacologic management. CNS Spectr 6:1-7.
6. Davidson JRT, Dupont RL, Hedges D, Haskins JT. 1999. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528-535.
7. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. 1989a. The Yale-Brown Obsessive Compulsive Scale: II. Validity. Arch Gen Psychiatry 46:1012-1016.
8. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. 1989b. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
9. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
10. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 25:56-67.
11. Kobak KA, Greist JH, Jefferson JW, Mundt JC, Katzelnick DJ. 1998. Computerized assessment of depression and anxiety over the telephone using interactive voice response. MD Computing 16:64-68.
12. Laakman G, Schüle C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. 1998. Buspirone and lorazepam in the treatment of generalized anxiety disorders in outpatients. Psychopharmacology 136:357-366.
13. Lieh YT, Liang HC, Kuang YY, Dar LY, Cheng CC, See CP. 2004. The adjustment to illness in patients with generalized anxiety disorder is poorer than that in patients with end-stage renal disease. J Psychosom Res 57:165-170.
14. Meoni P, Salinas E, Brault Y, Hackett D. 2001. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry 62:888-893.
15. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. 1990. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 28:487-495.
16. Molina S, Borkovec TD. 1994. The Penn State Worry Questionnaire: Psychometric properties and associated characteristics. In: Davey GCL, Tallis F, editors. Worrying: Perspectives on theory, assessment and treatment. Wiley Series in Clinical Psychology. New York: Wiley. p 265-283.
17. Möller HJ, Volz HP, Reimann IW, Stoll KD. 2001. Opipramol for the treatment of generalized anxiety disorder: A placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21:59-65.
18. Mundt JC, Kobak KA, Taylor LV, Mantle JM, Jefferson JW, Katzelnick DJ, Greist JH. 1998. Administration of the Hamilton Depression Rating Scale using interactive voice response technology. MD Computing 15:15-19.
19. Pollack MH, Zaninelli R, Goddard A, McCaffery JP, Bellew KM, Burnham DB, Lyengar MK 2001. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:350-357.
20. Rollman BL, Herbeck Belnap B, Reynolds C, Schulberg H, Shear M. 2003. A contemporary protocol for the treatment of panic and generalized anxiety in primary care. Gen Hosp Psychiatry 25:74-82.
21. Rollman BL, Herbeck Belnap B, Mazumdar S, Houck P, Zhu F, Gardner W, Reynolds CF, Schulberg HC, Shear MK. 2005. A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch Gen Psychiatry 62:1332-1341.
22. Roy-Byrne PP, Wagner A. 2004. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 65:20-26.
23. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA. 1997. Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154:1571-1575.
24. Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, Pollack MH, Chandler L, Williams J, Ali A, Frank DM. 2001. Reliability and validity of a Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 13:166-178.
25. Sheehan DV. 2001. Attaining remission in generalized anxiety disorder: Venlafaxine extended release comparative data. J Clin Psychiatry 62:26-31.
26. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV 3rd, Hahn SR, Brody D, Johnson JG. 1994. Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-AID 1000 study. JAMA 272(22):1749-1756.